COVID-19: Case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities
Aghili, R.; Honardoost, M.; Khamseh, M.E.
Medical Journal of the Islamic Republic of Iran 34: 147
2020
ISSN/ISBN: 1016-1430 PMID: 33437743 Accession: 071382456
The Corona Virus Disease 2019 (COVID-19) outbreak is becoming pandemic with the highest mortality in patients with associated comorbidities. These RNA viruses containing 4 structural proteins usually use spike protein to enter the host cell. Angiotensin-converting enzyme 2 (ACE2) acts as a host receptor for the virus. Therefore, medications acting on renin-angiotensin-aldosterone system can lead to serious complications, especially in patients with diabetes and hypertension. To avoid this, other potential treatment modalities should be used in COVID-19 patients with associated comorbidities.